Product Pipeline
Corixa and its partners are evaluating the company’s adjuvants in a new generation of adult and pediatric vaccines that are designed to be safer, more effective and to protect against a broad range of diseases. MPL® adjuvant, Corixa’s flagship adjuvant, is a derivative of the lipid A molecule found in gram-negative bacteria, one of the most potent immunostimulants known. MPL adjuvant licenses have been granted to GlaxoSmithKline and Wyeth for development in a variety of infectious disease targets. Vaccines containing MPL adjuvant have completed or are in multiple late-stage clinical trials against diseases such as herpes, hepatitis B, human papilloma virus and malaria.

Products on the Market
Ribi Adjuvant System
Products in Clinical Trials
MPL adjuvant for hepatitis B
MPL adjuvant for herpes
RC-529 adjuvant for hepatitis B
vaccine for leishmaniasis
vaccine for tuberculosis
A business overview as well as information on Corixa's partners, management team, employment opportunities, and company contacts.
Corixa's products and adjuvants for research applications.
Product pipeline, therapeutic areas of focus, products, technology platforms, and publications.
Company reports, SEC filings, events calendar, stock quote, analyst list, and materials request.
Current and archived company press releases.
Product pipeline, therapeutic areas of focus, products, technology platforms, and publications.